Bicara Therapeutics Inc. - 8-K Filing
Bicara Therapeutics reported three-year follow-up data showing ficerafusp alfa plus pembrolizumab achieved an estimated 31% overall survival in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma, doubling the standard of care. The trial included dose cohorts with deep responses translating into durable outcomes across duration of response (DOR), progression-free survival (PFS), and OS.
Tickers: $BCAX